Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Adocia SAS Ends Collaboration with Eli Lilly and Co on Ultra-Fast Acting Insulin Analog


Monday, 29 Jul 2013 11:50am EDT 

Adocia SAS announced that it has agreed with Eli Lilly and Co not to continue further joint research under the licensing agreement signed in December 2011 relating to use of Adocia SAS's BioChaperone technology for the formulation of fast acting insulin analog formulated with the BioChaperone technology. Consequently, the two companies have terminated the collaboration. Adocia SAS Intends to pursue the project by itself. 

Company Quote

67.32
0.47 +0.70%
26 Nov 2014